Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

11 months ago CAR-T

TIL Therapy: Revolutionizing Cancer Treatment Worldwide! China Accelerates into the Fast Lane!

🌟 TIL Therapy: Revolutionizing Cancer Treatment Worldwide! 🌎 China Accelerates into the Fast Lane!

📈 The number of cell immunotherapy trials for solid tumor treatment has surged globally, with a staggering growth from 66 in 2020 to 140 in 2022, a remarkable 110% increase! Particularly, TIL therapy trials have seen a remarkable surge, now accounting for 17.1% of all solid tumor treatments, sparking a new trend in cancer therapy that’s capturing the attention of researchers and companies alike.

🎯 TIL therapy boasts natural advantages in solid tumor treatment, boasting rich tumor-specific target points, robust tumor infiltration capabilities, and minimal side effects.

🔬 On February 16, 2024, the U.S. FDA officially greenlights Iovance Biotherapeutics’ lifileucel therapy for unresectable or metastatic melanoma, a groundbreaking personalized T-cell therapy using TIL sourced from the patient’s body.

FDA

🚀 In early 2022, China’s Grit Biotechnology’s GT101 injection became the first TIL product to enter clinical trials, signaling China’s entry into the global TIL therapy scene. With players like Juncell Therapeutics, LANMA BIO, and BT Gillion joining the fray, Chinese TIL therapy is on the fast track to development, exploring various indications including melanoma, cervical cancer, lung cancer, and more!

TIL therapy

💰 According to Sullivan’s forecast, the global CGT market is set to skyrocket to $22 billion by 2025, with TIL therapy leading the charge.

💡 Chinese TIL therapy is paving its own path to commercialization and industrialization, offering cost-effective treatments compared to the U.S. Stay tuned for more innovations in cancer therapy from China! 🇨🇳

🌟We have access to medical resources from all cancer hospitals in China and can assist patients in receiving treatment from the best and top-tier oncologists in the CHINA.

doctor.huang@globecancer.com

WhatsApp+8613717959070

#TILTherapy #CancerTreatment #Innovation #MedicalBreakthroughs #ChinaHealthcare #GlobalHealthcare #CancerResearch 🚀🔬

11 months ago CAR-T

Unlocking the Potential: Understanding TIL Therapy for Solid Tumors

🔍 Unlocking the Potential: Understanding TIL Therapy for Solid Tumors🧬

💡What is TIL therapy?🧬

According to the immune editing theory, during the process of tumor development, the body’s immune cells always play a role in killing tumor cells. Different immune cells (mainly lymphocytes) are transported to the tumor site, and these lymphocytes that have infiltrated into the tumor tissue and exerted cytotoxic effects are called tumor-infiltrating lymphocytes (TILs), including T cells, B cells, NK cells, macrophages, and various mononuclear and multinuclear immune cells, which can recognize, resist, attack, and kill tumors.

TIL therapy belongs to Cellular Immunotherapy, which is a method of treating using immunocytes that are activated, proliferated, or genetically engineered. The main steps include isolating specific immune-active cells (including T cells, NK cells, DC cells, and macrophages) from tumor patients, genetic modification or amplification in vitro, functional identification, and finally, returning for treatment.

Cancer Development

Understanding Cancer Development: Immune Surveillance, Immune Equilibrium, and Immune Escape ��

TIL therapy refers to isolating tumor-infiltrating lymphocytes from tumor tissue, culturing them in vitro, expanding them massively, and then reinfusing them into the body for treatment.

TIL Therapy

🔬 The main routine steps of TIL therapy include:

1. Obtaining patient tumor tissue: mainly obtained through surgery or biopsy to include TIL cells.

2. Grinding tumor tissue: This step makes it easier for T lymphocytes to grow and expand from tumor tissue.

3. Adding interleukin-2 (IL-2) for cultivation: After adding a high concentration of IL-2, on the one hand, it provides survival signals for existing TIL cells, and on the other hand, stimulates larger-scale proliferation.

4. Conducting tumor-specific recognition testing: By conducting tumor-specific recognition testing on TIL cells, screening for TIL preparation processes that can more specifically kill tumors to ensure treatment effectiveness.

5. Reinfusion of expanded TIL cells for treatment: Reinfusing expanded and screened TIL cells into the patient’s body to achieve the treatment goal.

💪Characteristics of TIL therapy:

1. Rich in tumor-specific targets: TIL cells naturally infiltrate tumor sites and naturally have TCR clones capable of recognizing multiple tumor-specific antigens. Therefore, after cultivation and expansion, they can recognize and target multiple tumor antigens, thereby overcoming tumor heterogeneity and achieving broad-spectrum killing of cancer cells.

2. Good tumor tropism and strong infiltration ability: TIL cells have successfully infiltrated tumor tissue before and have a chemokine expression profile more related to peripheral blood T cells. Therefore, after reinfusion into the body, they will be attracted by tumor-related chemokines to better reach and infiltrate tumor tissue.

3. High safety and low cytotoxicity: TIL cells are immune cells already present in human tumor tissue and have undergone screening during early thymic development. Therefore, after reinfusion, they will not exert cytotoxic effects on other cells in the human body, demonstrating high safety. No major side effects have been observed since the development of TIL therapy.

🌟Therefore, TIL therapy is considered one of the most competitive and industrialized potential immunocyte therapy methods in the field of solid tumors. The approval of the world’s first TIL therapy for solid tumor treatment once again confirms this.

“If you’d like to inquire about the latest cancer-fighting technologies and treatments, you can contact us.”

whatsapp: 137 1795 9070

#TILTherapy #CancerTreatment #Immunotherapy #MedicalInnovation ##tils

11 months ago CAR-T

Breaking News: Another Milestone for Domestic CAR-T Therapy! Clinical Benefit Rate Reaches 71.4% in CT041 Trials, Challenging Gastric and Pancreatic Cancers with Astonishing Results!

🎉 Breaking News: Another Milestone for Domestic CAR-T Therapy! Clinical Benefit Rate Reaches 71.4% in CT041 Trials, Challenging Gastric and Pancreatic Cancers with Astonishing Results! 🚀

Gastric Cancer， Pancreatic Cancer

A burgeoning therapeutic target for gastric cancer—Claudin 18.2, its discovery has also opened a new chapter in targeted therapy for gastric cancer. If we talk about the hottest cell immunotherapy in recent years, it has to be chimeric antigen receptor T-cell (CAR-T) therapy. Based on this, Chinese researchers have developed the world’s first CAR-T cell therapy targeting Claudin18.2—CT041.

CT041, as the first CAR-T cell therapy targeting Claudin18.2, made its debut at the 2019 ASCO Annual Meeting. Among 12 patients with metastatic adenocarcinoma (7 gastric cancer, 5 pancreatic cancer) treated with Claudin18.2-targeting CAR T-cell therapy, no severe adverse events, treatment-related deaths, or serious neurotoxicity were reported. Among the 11 evaluated patients: 1 (gastric adenocarcinoma) achieved complete remission; 3 (2 gastric adenocarcinoma, 1 pancreatic adenocarcinoma) achieved partial remission; 5 had stable disease; and 2 experienced disease progression. The overall objective response rate was 33.3%.

At the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) held on January 19, 2024, SciGen showcased a clinical study of Claudin18.2-targeting autologous CAR-T cell therapy CT041 (satri-cel), reporting results from the dose escalation phase of the ELIMYN18.2 1b clinical trial conducted in the United States for the treatment of gastric/esophagogastric junction adenocarcinoma (GC/GEJ) or pancreatic cancer (PC).

This single-arm, open-label phase 1b/2 study primarily evaluated the safety and efficacy of CT041 in patients with advanced Claudin18.2-positive gastric/esophagogastric junction adenocarcinoma (GC/GEJ, progressing after at least second-line treatment or intolerant) or pancreatic cancer (PC, progressing after at least first-line treatment or intolerant).

Nineteen patients (9 GC/GEJ patients, 12 PC patients) received CT041 treatment at doses ranging from 250 to 600×106 cells: dose 1: 250-300×106 (n=6), dose 2: 375-400×106 (n=6), dose 3: 600×106 (n=7). All patients had received systemic therapy, with 85.7% of GC/GEJ patients and 58.3% of PC patients receiving ≥3 lines of systemic therapy. The median number of metastatic organs for all patients was 2, with at least one prior infusion. Clinical benefit rate included complete remission [CR], partial remission [PR], and stable disease [SD] ≥180 days.

As of September 15, 2023, with a median follow-up of 8.9 months, across all dose groups, the confirmed objective response rate (ORR) for gastric/esophagogastric junction adenocarcinoma patients was 42.9% (3/7); clinical benefit rate (CBR) was 57.1% (4/7); median progression-free survival (mPFS) and median duration of response (mDOR) were 5.7 months and 6.9 months, respectively. Additionally, the median overall survival (mOS) for gastric/esophagogastric junction adenocarcinoma or pancreatic cancer patients was 8.9 months. In dose level 3 (DL3), one gastric/esophagogastric junction adenocarcinoma patient achieved complete remission (CR). The clinical benefit rate for gastric/esophagogastric junction adenocarcinoma or pancreatic cancer patients was 71.4% (5/7), with a median OS of 12.9 months.

In summary, #CT041, as the first autologous #Claudin182 CAR-T cell therapy, demonstrates encouraging safety and shows promising preliminary efficacy in Claudin18.2-positive advanced GC/GEJ and PC patients who have received multiple prior treatments.

You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address: doctor.huang@globecancer.com, or click on the WhatsApp+8613717959070 icon on the homepage. The Medical Department will contact you as soon as they receive the reports.

🌟 #CART #Immunotherapy #CT041 #CancerResearch #ClinicalTrials #GastricCancer #PancreaticCancer #SciGen #ASCOGI2024

12 months ago CAR-T

Breakthrough! Chinese Novel CAR-T Therapy Kills Tumors and Prevents Relapse!

🌟✨ Breakthrough! Chinese Novel CAR-T Therapy Kills Tumors and Prevents Relapse! ✨🌟

CAR-T Therapy

🔬 On January 2, 2024, a groundbreaking clinical study from China was published in *Nature*. This study, employing engineering design, enables CAR-T cells to secrete Interleukin-10 (IL-10), thereby enhancing metabolism within the tumor microenvironment. The modified IL-10 CAR-T cells increase oxidative phosphorylation in a mitochondrial acetoacetate carrier-dependent manner, resulting in complete regression of solid tumors and metastatic cancers, including colon cancer, breast cancer, melanoma, and pancreatic cancer. This breakthrough research offers new hope for cancer patients.

🌱 The Miracle of IL-10 🌱

The secretion of IL-10 promotes the proliferation and effector functions of CAR T cells, leading not only to the regression of solid tumors but also inducing stem cell-like memory responses in lymphoid organs, providing enduring protection against tumor re-attack. Specifically, IL-10 HER2 CAR-T cells achieved complete regression of MC38-HER2 tumors in mice, with a cure rate of 90%. In the case of melanoma, IL-10 TRP-1 CAR-T cells achieved a clearance rate of 60%, with significant success in treating the orthotopic B16F10 melanoma model.

🦠 A Weapon against Relapse 🦠

In addition to complete regression of solid tumors, IL-10 CAR-T cells demonstrated the ability to prevent relapse in immunodeficient mice. Mice treated with IL-10 CD19 hCAR-T cells for Raji or PANC1-CD19 tumors exhibited complete tumor regression without relapse, indicating stronger anti-tumor capabilities of IL-10 CAR-T cells in xenograft models. Particularly noteworthy is the effective elimination of pancreatic ductal adenocarcinoma (PDAC) tumors by IL-10 CD19 hCAR-T cells, resulting in complete response in all treated mice.

💊 A Revolutionary Treatment Approach 💊

These findings suggest that IL-10-expressing CAR-T cells are an effective immunotherapy against various solid tumors, capable of achieving complete regression in multiple synthetic and xenograft tumor models. What’s more exciting is that preliminary results indicate the metabolism-enhanced IL-10 CD19 CAR-T cell therapy developed by Leman Biotech requires extremely low treatment doses, consistently achieving complete remission in numerous relapsed/refractory lymphoma or leukemia patients, paving the way for a new era in cancer treatment.

✨ A Beacon of Hope ✨

This breakthrough study brings hope to cancer patients and demonstrates the immense potential of CAR-T therapy in cancer treatment. Looking ahead, further advancements in this technology promise to provide more opportunities for recovery and survival to patients worldwide. Let’s anticipate more breakthroughs together and strive towards conquering cancer

To assess whether the condition is suitable for CAR-T therapy, you can submit Advanced Medicine in China for preliminary evaluation!

Email: doctor.huang@globecancer.com,

WhatsApp: +8613717959070

#all #CARTtherapy #CancerTreatment #RRMM #IL10 #Tumor #Nature #MedicalBreakthrough #CARTCELL #coloncancer #breastcancer #melanoma #pancreatic 🌟🔬💊

12 months ago CAR-T

Innovative Breakthrough: Chinese Team Creates Novel CAR-T Cells Using CRISPR/Cas9 Technology

🔬 Innovative Breakthrough: Chinese Team Creates Novel CAR-T Cells Using CRISPR/Cas9 Technology 🔬

Nature

The clinical research achievements conducted by Professor Huang He’s team from the First Affiliated Hospital of Zhejiang University School of Medicine have been published online in the top international journal Nature under the title “Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL.”

In the field of CAR-T cells, we face numerous challenges. However, the collaboration between Professor Liu Mingyao’s team and Director Huang He’s team has introduced the innovative CRISPR/Cas9 gene editing technology into CAR-T therapy, bringing us unprecedented breakthroughs. They precisely utilized CRISPR/Cas9 technology to remove the “brake” PD1 from T lymphocytes and inserted the targeted CD19 CAR molecule for tumor cells, creating a brand-new non-viral targeted integration CAR-T cell (PD1-19bbz).

💡 Analyzing the Scientific Principles behind the Technology 💡

CRISPR/Cas9 can be likened to a “gene editing scissors,” with PD1 being the “brake” on T cells. By precisely removing the PD1 locus with the “scissors” and inserting the “GPS navigation system” CD19 CAR molecule at the same position, we successfully eliminated the “brake” of CAR-T cells, turning them into efficient killers targeting tumors.

🧬 Groundbreaking Clinical Validation 🧬

Through rigorous clinical studies, we have confirmed the safety and efficacy of PD1-19bbz. Whether in tumor cells with high or low PD-L1 expression, PD1-19bbz has demonstrated more powerful and durable killing effects. What’s more exciting is that our research indicates PD1-19bbz achieves a 100% objective response rate and an 87.5% complete response rate in treating refractory relapsed lymphoma patients.

🌟 Pioneering a New Era in CAR-T Cell Therapy 🌟

This groundbreaking achievement brings new hope to CAR-T cell therapy. We have successfully established a brand-new CAR-T cell technology platform, providing a safer and more effective option for the treatment of refractory relapsed lymphoma and other diseases. This also signifies the leading position of Chinese scholars in the field of CAR-T cell research and development internationally.

💬 Expert Evaluation 💬

Professor Justin Eyquem from the University of California and Senior Editor Victoria Aranda from Nature highly praised our achievements: “This inspiring result demonstrates the excellent clinical safety and efficacy of this CAR-T therapy.”

We will continue to dedicate ourselves to advancing CAR-T cell therapy, bringing hope and health to more patients. Stay tuned for our progress!

🧶You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address:

🌈🌈📩doctor.huang@globecancer.com🌈🌈,

or click on the ☎️WhatsApp+8613717959070☎️ icon on the homepage.

The Medical Department will contact you as soon as they receive the reports.

#CARTCells #CRISPR #ScientificBreakthrough #CancerTreatment

12 months ago CAR-T

Exciting News Alert! China’s New TCR-T Product IND Approved for Synovial Sarcoma!

🌟 Exciting News Alert! China’s New TCR-T Product IND Approved for Synovial Sarcoma! 🌟

synovial sarcoma

“Engineered T Cell Receptor-T Cell Therapy,” or “TCR-T (engineered T cell receptor-T cell, TCR-T) cell therapy,” involves the extraction of peripheral blood mononuclear cell (PBMC) samples from patients, followed by genetic engineering to introduce selected high-affinity T cell receptors (TCRs) into T cells. This enables them to seek out and specifically recognize tumor antigens, effectively targeting and killing cancer cells.

In early 2022, the Food and Drug Administration (FDA) in the United States approved a TCR-T therapy called “Kimmtrack” for treating uveal melanoma, marking a significant milestone in solid tumor treatment.

Recently, the prestigious international journal “Cell Rep Med” reported the Phase I clinical trial results of China’s first investigational new drug (IND) approved by the FDA for TCR-T cell therapy — TAEST16001. This groundbreaking research represents a crucial step forward in the clinical translation of adoptive T cell immunotherapy for advanced soft tissue sarcoma and holds the potential to become the world’s second marketed TCR-T cell therapy targeting solid tumors!

Cell Rep Med

China’s first TCR-T product IND approval takes aim at synovial sarcoma.

TAEST16001,

developed independently by Xiangxue Life Sciences, is a TCR-T cell product. The Phase I clinical trial enrolled 12 patients with advanced soft tissue sarcomas who were HLA-A*02:01 positive and expressed the NY-ESO-1 antigen. Among them, 10 patients had synovial sarcoma, while 2 had liposarcoma (1 myxoid liposarcoma and 1 dedifferentiated liposarcoma), with a median age of 33 (25-67) years. 58.3% (7/12) of patients were male. Before enrollment, 83.3% of patients had received at least two types of chemotherapy. After enrollment, all patients underwent modified lymphocyte clearance surgery followed by infusion treatment with TAEST16001 cells.

After a median treatment duration of 43 days, 9 out of 12 patients (75%) showed tumor regression (Figure 1), with a median time to response (TTR) of 1.9 months and a median duration of response of 13.1 months. Six patients (50%) exhibited sustained tumor burden reduction after the first radiological assessment. In the primary analysis, 5 out of 12 patients achieved partial responses, resulting in an objective response rate (ORR) of 41.7% (95% CI, 15.2–72.3). Disease stabilization was observed in 5 cases [41.7% (95% CI, 15.2–72.3)], yielding a disease control rate of 83.3% (95% CI, 51.6–97.9). The median progression-free survival (PFS) was 7.2 months (95% CI, 2.5–11.8).

TCR-T Therapy

How to Seek TCR-T Therapy Assistance

Several TCR-T therapies under development in China are urgently recruiting patients with hepatitis B virus-related liver hepatocellular carcinoma, head and neck tumors (oral cancer, laryngeal cancer, etc.), advanced cervical cancer, and anal cancer.

If you wish to assess whether your condition is suitable for CAR-T therapy, you can submit your pathological reports, treatment history, and discharge summaries to

<Advanced Medicine in China> doctor.huang@globecancer.com for preliminary evaluation.

or click on the WhatsApp+8613717959070

Stay tuned for more updates on this groundbreaking advancement in cancer treatment! 🌟

#CancerResearch #TCRTtherapy #SynovialSarcoma #MedicalInnovation

12 months ago CAR-T

A New Era in Lung Cancer Treatment – Serplulimab Brings Innovative and Reliable Therapeutic Options!

🌟 A New Era in Lung Cancer Treatment – Serplulimab Brings Innovative and Reliable Therapeutic Options! 🌟

Cancer cell

📆CANCER CELL

January 5, 2023: The highly anticipated Phase 3 pivotal clinical trial (ASTRUM-004) of HANSIZHUANG, an anti-PD-1 monoclonal antibody developed independently by Henlius, in combination with chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer (sqNSCLC), has just been published in the prestigious international oncology journal “Cancer Cell” (Impact Factor: 50.3)! Led by Professor Zhou Caicun from Shanghai Pulmonary Hospital, this milestone study signifies a significant breakthrough in lung cancer treatment.

🔬 Lung cancer

is one of the most common cancers globally, with the highest reported incidence and mortality rates in China. According to the latest statistics from the National Cancer Center, there are 828,000 new cases of lung cancer and 657,000 deaths annually. Non-small cell lung cancer (NSCLC) accounts for approximately 80% to 85% of all lung cancers, with a significant proportion diagnosed at an advanced stage or with metastasis, unsuitable for surgical resection.

🌱NSCLC

In the field of NSCLC treatment, immune checkpoint inhibitors have become a game-changer. Serplulimab is the first innovative monoclonal antibody developed independently by Henlius. Since its approval in March 2022, it has been approved in China for the treatment of microsatellite instability-high (MSI-H) solid tumors, sqNSCLC, extensive-stage small cell lung cancer (ES-SCLC), and esophageal squamous cell carcinoma (ESCC), benefiting over 51,000 patients.

🔍 ASTRUM-004

is a pivotal Phase 3 trial aimed at evaluating the efficacy and safety of serplulimab in combination with chemotherapy as first-line treatment for advanced sqNSCLC. The results are promising: patients receiving serplulimab demonstrated significantly prolonged progression-free survival (PFS) and overall survival (OS), with manageable safety profiles.

Serplulimab

🎉NEW ERA

These findings herald a new era in lung cancer treatment, offering a ray of hope for patients and clinicians alike. Serplulimab in combination with chemotherapy has emerged as a promising first-line treatment option, bringing innovation and reliability to sqNSCLC patients.

👩‍🔬Lead

Lead investigator Professor Zhou Caicun commented, “The ASTRUM-004 study validates the significant potential of serplulimab in combination with chemotherapy to improve survival outcomes in sqNSCLC patients, marking a major breakthrough in the field of lung cancer.”

🌟 Stay tuned for more updates as we continue to unravel the mysteries of cancer treatment, bringing hope to millions worldwide!

#CancerResearch #LungCancer #MedicalBreakthrough #InnovationForHealth #Serplulimab #NSCLC #ASTRUM #sqNSCLC #cancercell

12 months ago CAR-T

Chinese Hengrui Pharmaceuticals ‘s indication for cervical cancer has been approved for clinical trials.

🌟 Chinese Hengrui Pharmaceuticals ‘s indication for cervical cancer has been approved for clinical trials.🌟

cervical cancer

🏥💊（Jiangsu Hengrui Pharmaceuticals Co., Ltd）Hengrui Pharmaceutical’s PD-L1 inhibitor Atezolizumab injection combined with concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer has been approved for open, multicenter Phase II clinical trials.

Atezolizumab

🌸🎀#Cervical cancer is the fourth most common cancer in women globally, mainly caused by persistent infection with high-risk human papillomavirus (#HPV). Although the widespread implementation of #cervicalcancer screening and the availability of HPV vaccines have reduced the incidence of cervical cancer in developed countries, it remains one of the common malignant tumors in women.

🏥💊Atezolizumab injection is a humanized anti-PD-L1 monoclonal antibody independently developed by Hengrui Medicine. It is the first PD-L1 inhibitor approved for the treatment of small cell lung cancer in China. By specifically binding to the PD-L1 molecule, it blocks the PD-1/PD-L1 pathway that leads to tumor immune tolerance, reactivating the immune system’s anti-tumor activity and achieving the goal of tumor treatment.

The Lancet Oncology

🌸🎀Atezolizumab injection has been studied in various fields, including small cell lung cancer, #NSCLC non-small cell lung cancer, esophageal cancer, liver cancer, and cervical cancer. It has shown promising efficacy in small cell lung cancer. Based on the results of the SHR-1316-III-301 study, the application for the market approval of Atezolizumab injection combined with chemotherapy as first-line treatment for extensive-stage small cell lung cancer has been accepted and approved in China in March 2023. The study results have been published in the top international medical journal “The Lancet Oncology,” and the original research from China has been internationally recognized.

🏢💊Jiangsu Hengrui Pharmaceuticals Co., Ltd is committed to advancing the clinical research of the PD-L1 inhibitor Atezolizumab injection, bringing more innovative and effective treatment options for cervical cancer patients. Stay tuned for our progress!

Hengrui Pharmaceutical

🚑In addition to Cervical cancer, we are currently urgently recruiting patients with B-cell lymphoma, T-cell lymphoma, T-cell leukemia (T-ALL), acute lymphoblastic leukemia, myeloma, and other types of cancer!

You can send electronic copies or photos of genetic testing reports and diagnostic reports to the 📩email address: doctor.huang@globecancer.com📩, or click on the ✉️WhatsApp+8613717959070✉️ icon on the homepage. The Medical Department will contact you as soon as they receive the reports.

#CervicalCancerTreatment #Atezolizumab #HengruiMedicine #ClinicalTrials #CancerTreatment #cervical #cervicalcancer #chinesemedicine #newdrug #Lancet #TheLancetOncology

📩References：　　

[1]gco.iarc.fr(WHO statistics)

　　[2]Rose PG,Bundy BN,Watkins EB,Thigpen JT,Deppe G,Maiman MA,Clarke-Pearson DL,Insalaco S:Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.N Engl J Med1999,340(15):1144-1153.

　　[3]Pfaendler KS,Tewari KS:Changing paradigms in the systemic treatment of advanced cervical cancer.Am J Obstet Gynecol2016,214(1):22-30.

　　[4]Liu C,Lu J,Tian H,Du W,Zhao L,Feng J,Yuan D,Li Z:Increased expression of PDL1by the human papillomavirus16E7oncoprotein inhibits anticancer immunity.Mol Med Rep2017,15(3):1063-1070.

12 months ago CAR-T

Chinese Exciting Good News Update in Lung Cancer Treatment! ORR: 78.6%

Meet Sunvozertinib, the game-changer in advanced lung cancer therapy!

Sunvozertinib, NSCLC

This groundbreaking oral medication, a novel irreversible EGFR-TKI, targets multiple EGFR mutation subtypes with remarkable precision. What’s more? Sunvozertinib is now the FIRST and ONLY EGFR-TKI approved for treating late-stage NSCLC with EGFR exon20ins mutations!

At the 2023 ESMO Conference, fresh data from early trials of Sunvozertinib’s frontline treatment for EGFR exon20ins-mutated advanced NSCLC were unveiled, and the results were jaw-dropping!

With an astounding Objective Response Rate (ORR) of 78.6% and a median Progression-Free Survival (PFS) of 12.4 months at the recommended dose (300mg QD), Sunvozertinib once again set a new benchmark in this field, offering a superior treatment option for newly diagnosed patients with EGFR exon20ins mutations!

Let’s dive into a real success story: A 35-year-old male diagnosed with late-stage NSCLC harboring EGFR exon20ins mutations, along with metastases to the brain, liver, and bones. After showing stable disease (SD) following two cycles of platinum-based chemotherapy, he switched to Sunvozertinib. Just one month into treatment, a follow-up chest CT scan revealed a remarkable 34% reduction in the size of the left lower lobe lesion, with lung lesions shrinking from 29mm×26mm to 19mm×15mm (see image). Multiple nodules in the lungs and pleura also decreased in size, along with liver lesions. Evaluation: Partial Response (PR)!

Lung Cancer

Noteworthy is the impeccable safety profile of Sunvozertinib, with no significant adverse effects reported during treatment. As of this post, the patient continues to receive Sunvozertinib monotherapy with promising outcomes!

With breakthroughs in targeted therapies for EGFR exon20ins-mutated NSCLC, several new drugs are actively exploring frontline treatment options. The early study results of Sunvozertinib’s frontline therapy for EGFR exon20ins-mutated advanced NSCLC have once again rewritten the records in this field, providing new treatment guidelines for these patients!

#LungCancerAwareness #Sunvozertinib #EGFRexon20ins #NSCLC #TargetedTherapy #MedicalBreakthroughs #HealthcareInnovation #lungs #lung #lungcancer #chinesemedicine #EGFR

12 months ago CAR-T

Breakthrough in Cancer Treatment in CHINA: TX103 CAR-T Approved for Clinical Use Against Recurrent Brain Gliomas

🔬”Breakthrough in Cancer Treatment in CHINA: TX103 CAR-T Approved for Clinical Use Against Recurrent Brain Gliomas”🔬🧠

Brain Gliomas

✨ Exciting news in cancer research! Fuzhou Tuoxin Tiancheng Biotech’s TX103 CAR-T, a revolutionary therapy for recurrent stage 4 gliomas, has received clinical approval. 🌟 🧠

#CancerTreatment #MedicalInnovation #TX103CAR_T #CAR_T #Tumor #solidtumor #brainglioma #glioma

Article:

Fuzhou Tuoxin Tiancheng Biotech Co., Ltd. (“Tuoxin Tiancheng”) has achieved a significant milestone with the clinical approval of their “TX103 Chimeric Antigen Receptor T-cell Injection” (TX103 CAR-T) for the treatment of recurrent or progressive stage 4 brain gliomas.🧠

TX103 CAR-T is a targeted therapy focusing on B7-H3. The B7-H3 target belongs to the B7 ligand family, showing excessive expression in various cancers while maintaining low or no expression in normal tissues. B7-H3 possesses non-immunogenic functions such as promoting migration and invasion, angiogenesis, chemotherapy resistance, endothelial-to-mesenchymal transition, and influencing tumor cell metabolism. Its expression in tumors is associated with poor prognosis, making it valuable in tumor immunotherapy.🧠

The therapy has already been approved for clinical trials in both China and the United States, with this recent approval marking a new indication. In August 2022, TX103 received clinical approval for the treatment of late-stage solid tumor patients who are TX103 positive, have failed standard treatments, or experienced intolerable toxicity after standard treatments with a confirmed pathological diagnosis.🧠

In September of the previous year, Tuoxin Tiancheng announced that their TX103 CAR-T cells, in collaboration with Tcelltech in the United States, received FDA approval for Investigational New Drug (IND) status for the treatment of malignant brain gliomas. This achievement represents a crucial milestone in Tuoxin Tiancheng’s efforts to address solid tumor treatments and promote internationalization. According to a Tuoxin Tiancheng press release, early clinical trial studies with TX103 in treating recurrent malignant brain gliomas demonstrated promising safety and efficacy signals. Furthermore, TX103 CAR-T for the treatment of malignant brain gliomas received orphan drug designation from the FDA in June 2023.🧠

Tuoxin Tiancheng

Tuoxin Tiancheng is a clinical-stage innovative biopharmaceutical company focused on developing T cell immunotherapy products. Founded by Professor Chen Lieping, a pioneer in tumor immunology, and Professor Huang Gangxiong, an expert in immunotherapy, the company is dedicated to advancing innovative technologies and drugs in tumor immunotherapy and immunocellular therapy. With a professional team covering scientific research, technical development, quality management, production processes and registration, the company has taken a significant step forward with this clinical approval. We look forward to Tuoxin Tiancheng bringing more cutting-edge products to benefit patients. 🧠

#BiopharmaInnovation #ImmunotherapyAdvancement #TuoxinTianchengBiotech #chinesemedicine

1 year ago CAR-T

Revolutionizing Medicine: CAR-T Therapy Beyond Cancer

🚀Revolutionizing Medicine: CAR-T Therapy Beyond Cancer 🚀

🔬 Over the past decade, CAR-T cell therapy has transformed the field of oncology, successfully treating previously incurable blood cancers. While CAR-T therapy gained fame for its success in cancer treatment, the roots of this groundbreaking principle trace back nearly 30 years—initially exploring T cell therapy for HIV/AIDS. Although the early attempts didn’t succeed in treating HIV/AIDS, they demonstrated the enduring potential of engineered T cells in immunocompromised patients.

🌟 CAR-T therapy, or Chimeric Antigen Receptor T-cell Immunotherapy, essentially involves reengineering a patient’s immune T cells outside the body to recognize antigens on the surface of tumor cells. These modified cells are then reintroduced into the patient, effectively identifying and eliminating cancer cells. Scientists have been tirelessly working to extend CAR-T therapy beyond blood cancers to various other types.

💡 Moreover, research from both clinical and preclinical studies indicates that CAR-T therapy holds great promise beyond cancer treatment. It shows potential applications in autoimmune diseases, chronic infections, heart diseases, aging-related conditions, and more.

🌐 In recent years, scientists have focused on applying CAR-T therapy to solid tumors, exploring its potential in cancer types beyond blood-related malignancies. Early research results suggest that the next frontier for CAR-T therapy may extend to various fields outside cancer, including autoimmune diseases (systemic lupus erythematosus, pemphigus vulgaris, multiple sclerosis, type 1 diabetes, asthma), fibrotic diseases (fibrosis in the heart, liver, lungs, and kidneys), aging-related conditions (liver fibrosis, solid tumors, atherosclerosis, natural aging), and infectious diseases (HIV/AIDS, hepatitis B and C, pulmonary tuberculosis).

🚀 The future of CAR-T therapy holds vast potential in reshaping the landscape of medical treatment, reaching far beyond the realms of cancer. Stay tuned for ground

#immunotherapyrevolution #CARTTherapy #MedicalInnovation #BeyondCancer #ImmunotherapyRevolution #CART #cancer #tumor #cancertreatment #tcell

1 year ago CAR-T

China Leading Global Advances in Breast Cancer Immunotherapy

🌟China Leading Global Advances in Breast Cancer Immunotherapy 🌟#ChinaInMedicine #BreastCancer

Breast Cancer

Since 2020, breast cancer has surpassed lung cancer, becoming the most common cancer globally with approximately 2.3 million new cases and 680,000 deaths annually. Despite improvements in traditional treatments like surgery, chemotherapy, and radiation, the mortality rate remains high. China’s Chimeric Antigen Receptor (CAR) immunotherapy is making significant strides, spearheading innovation in breast cancer treatment. 🇨🇳💪

Recent studies indicate substantial breakthroughs in CAR-T therapy, as well as CAR-NK cells and CAR macrophages for breast cancer treatment. The application of combination therapies further enhances the cytotoxicity of CAR-based cell therapies against breast cancer cells, bringing new hope to patients. 🚀

China is at the forefront of global clinical research on CAR, with 16 clinical trials focused on CAR-T or CAR-NK cell therapies currently underway. Particularly noteworthy is the research at the People’s Liberation Army General Hospital, where CAR-T cells targeting CD133 are employed to treat refractory advanced malignant tumors, including breast cancer. This approach has demonstrated excellent anti-tumor activity and manageable safety in patients previously treated for advanced hepatocellular carcinoma and cholangiocarcinoma. 🏥✨

On another front, the clinical study at Sun Yat-sen Memorial Hospital, Zhongshan University, is equally intriguing. They are exploring PD-1 knockout CAR-T cells targeting MUC1 for treating late-stage breast cancer patients. This trial is a dose-escalation exploratory study, and researchers anticipate its results to pave the way for future treatments. 🧪🔍

China is not only a trailblazer in breast cancer immunotherapy research but also a miracle creator, bringing new hope to cancer patients worldwide. Let’s witness China’s outstanding achievements in the medical field and acknowledge its contribution to global health! 💊🌏

#ImmunotherapyAdvancements #BreastCancerResearch

Menu

Tags Archives: Cancer Treatment

🌟 **TIL Therapy: Revolutionizing Cancer Treatment Worldwide! 🌎** China Accelerates into the Fast Lane!

🔍 Unlocking the Potential: Understanding TIL Therapy for Solid Tumors🧬

💡What is TIL therapy?🧬

🔬 The main routine steps of TIL therapy include:

💪Characteristics of TIL therapy:

🌟✨ **Breakthrough! Chinese Novel CAR-T Therapy Kills Tumors and Prevents Relapse!** ✨🌟

🌱 **The Miracle of IL-10** 🌱

🦠 **A Weapon against Relapse** 🦠

💊 **A Revolutionary Treatment Approach** 💊

✨ **A Beacon of Hope** ✨

🔬 Innovative Breakthrough: Chinese Team Creates Novel CAR-T Cells Using CRISPR/Cas9 Technology 🔬

💡 Analyzing the Scientific Principles behind the Technology 💡

🧬 Groundbreaking Clinical Validation 🧬

🌟 Pioneering a New Era in CAR-T Cell Therapy 🌟

💬 Expert Evaluation 💬

🌟 Exciting News Alert! China’s New TCR-T Product IND Approved for Synovial Sarcoma! 🌟

China’s first TCR-T product IND approval takes aim at synovial sarcoma.

TAEST16001,

How to Seek TCR-T Therapy Assistance

or click on the WhatsApp+8613717959070

**🌟 A New Era in Lung Cancer Treatment – Serplulimab Brings Innovative and Reliable Therapeutic Options! 🌟**

📆CANCER CELL

🔬 Lung cancer

🌱NSCLC

🔍 ASTRUM-004

🎉NEW ERA

👩‍🔬Lead

🌟 Chinese Hengrui Pharmaceuticals ‘s indication for cervical cancer has been approved for clinical trials.🌟

🚑In addition to Cervical cancer, we are currently urgently recruiting patients with B-cell lymphoma, T-cell lymphoma, T-cell leukemia (T-ALL), acute lymphoblastic leukemia, myeloma, and other types of cancer!

Chinese Exciting Good News Update in Lung Cancer Treatment! ORR: 78.6%

Meet Sunvozertinib, the game-changer in advanced lung cancer therapy!

🔬”Breakthrough in Cancer Treatment in CHINA: TX103 CAR-T Approved for Clinical Use Against Recurrent Brain Gliomas”🔬🧠

✨ Exciting news in cancer research! Fuzhou Tuoxin Tiancheng Biotech’s TX103 CAR-T, a revolutionary therapy for recurrent stage 4 gliomas, has received clinical approval. 🌟 🧠

Article:

🚀Revolutionizing Medicine: CAR-T Therapy Beyond Cancer 🚀

🚀 The future of CAR-T therapy holds vast potential in reshaping the landscape of medical treatment, reaching far beyond the realms of cancer. Stay tuned for ground

🌟China Leading Global Advances in Breast Cancer Immunotherapy 🌟#ChinaInMedicine #BreastCancer

China is not only a trailblazer in breast cancer immunotherapy research but also a miracle creator, bringing new hope to cancer patients worldwide. Let’s witness China’s outstanding achievements in the medical field and acknowledge its contribution to global health! 💊🌏

Recent Posts

🌟 TIL Therapy: Revolutionizing Cancer Treatment Worldwide! 🌎 China Accelerates into the Fast Lane!

🌟✨ Breakthrough! Chinese Novel CAR-T Therapy Kills Tumors and Prevents Relapse! ✨🌟

🌱 The Miracle of IL-10 🌱

🦠 A Weapon against Relapse 🦠

💊 A Revolutionary Treatment Approach 💊

✨ A Beacon of Hope ✨

🌟 A New Era in Lung Cancer Treatment – Serplulimab Brings Innovative and Reliable Therapeutic Options! 🌟